X

Trial Profile

Effect of single and multiple doses of ritonavir on the pharmacokinetics of venetoclax.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ritonavir (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia
Focus Pharmacokinetics; Therapeutic Use

Most Recent Events

24 Mar 2018 Data from this trial was used to develop and validate a semi-mechanistic model of Ritonavir CYP3A-mediated drug-drug interaction (DDI) with Venetoclax, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
09 Jan 2018 New trial record
04 Jan 2018 Results published in the European Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com